CF10/LV overcomes acquired resistance to 5-FU/LV in colorectal cancer cells through downregulation of the c-Myc/ABCB5 axisCharles Chidi Okechukwu(Wake Forest University), William H. Gmeiner(Wake Forest University)Cancer Drug ResistanceJuly 15, 202510.20517/cdr.2025.76Cited by 2SaveCiteExport RISWatch citationsRelated PapersCF10 Displayed Improved Activity Relative to 5-FU in a Mouse CRLM Model Under Conditions of Physiological Folate|Cancers|2025|2The fluoropyrimidine polymer CF10 synergizes with 5-ethynyl-2′-deoxyuridine by promoting telomere attrition and mitotic catastrophe|NAR Molecular Medicine|2026|0CF10 Displays Improved Synergy with Oxaliplatin in TP53-Null and Wild-Type CRC Cells from Increased Top1cc and Replication Stress|Cancers|2026|0